InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers... Show more
INFU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 38 cases where INFU's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for INFU just turned positive on March 21, 2025. Looking at past instances where INFU's MACD turned positive, the stock continued to rise in of 61 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INFU advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on March 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on INFU as a result. In of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for INFU moved below the 200-day moving average on March 31, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INFU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for INFU entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.628) is normal, around the industry mean (23.715). P/E Ratio (195.127) is within average values for comparable stocks, (83.458). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.598) is also within normal values, averaging (41.612).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INFU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INFU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
a manufacturer of external ambulatory infusion pumps
Industry MedicalSpecialties
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
JNGLX | 67.84 | 0.80 | +1.19% |
Janus Henderson Global Life Sciences D | |||
MAGCX | 26.28 | 0.10 | +0.38% |
BlackRock Advantage Global Institutional | |||
ASCQX | 15.01 | N/A | N/A |
American Century Small Company I | |||
RBCRX | 9.85 | N/A | N/A |
RBC China Equity R6 | |||
THOVX | 38.44 | -0.01 | -0.03% |
Thornburg Global Opportunities R4 |
A.I.dvisor indicates that over the last year, INFU has been loosely correlated with XRAY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then XRAY could also see price increases.
Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
---|---|---|---|---|
INFU | 100% | -0.75% | ||
XRAY - INFU | 35% Loosely correlated | +1.50% | ||
ALGN - INFU | 34% Loosely correlated | +3.73% | ||
ANIK - INFU | 33% Loosely correlated | +0.13% | ||
SMTI - INFU | 33% Loosely correlated | -0.99% | ||
NVST - INFU | 33% Poorly correlated | +2.40% | ||
More |